Artistic initiatives turn cybersecurity into immersive exhibits at the Museum of Malware Art, transforming digital threats into thought-provoking experiences.
FDA greenlights Life Biosciences’ gene therapy study to rewind the age of cells
One of the biggest theories about the cause of aging, and how to slow and potentially even reverse it, is about to be put to the test. Life Biosciences, a biotech startup co-founded by Harvard …
Hand CVE Over to the Private Sector
How MITRE has mismanaged the world’s vulnerability database for decades and wasted millions along the way.
Boehringer signs €1bn+ deal for Simcere IBD candidate
Boehringer Ingelheim has sourced an IL-23p19xTL1A bispecific antibody for inflammatory bowel disease, from China’s Simcere, for €42m upfront.
Feasibility and reliability of a smartwatch to detect atrial fibrillation after cardiac surgery: a prospective study
BackgroundAtrial fibrillation, the world’s predominant cardiac arrhythmia, frequently emerges as a complication post-cardiac surgery, leading to serious outcomes like strokes, heart failures, and even death. Due to its often-silent nature, detecting it can be challenging. Smartwatches present a potential solution, offering screening that is more rigorous.ObjectiveThis prospective observational study sought to assess the Withings Scanwatch’s […]
Roche’s obesity shot posts decent weight loss in mid-stage test, heads to Phase 3
Roche’s most advanced obesity drug allowed patients in a Phase 2 trial who took it for nearly a year to lose 18.3% of their weight after correcting for placebo, the Swiss pharma
TRexBio gets another $50M to bring more Treg candidates into the clinic
Bay Area startup TRexBio has bolstered its 2024 Series B with an additional $50 million to fund the biotech’s clinical development in the burgeoning Treg space. The biotech, founded in 2018 by SV Health Investors …
Roche claims midstage win for obesity injectable
Roche reports weight loss of up to 22.5% with its injectable GIP/GLP-1 agonist obesity drug, setting up phase 3, but will it be too late to the table?
Vaccination fall costs UK its measles elimination status
The UK has lost its measles elimination status, according to the WHO, due to a spike in cases in 2024 and a fall in vaccination coverage.
Pfizer retains top spot in vaccine rankings as Sanofi’s slide sparks ‘code red’ call
Pfizer again heads up a physician ranking of vaccine manufacturers, beating Merck & Co. and Moderna to complete an unchanged top three from the last edition of the survey. But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good standing with physicians.
Introducing the Sunday Times Tech 100: Life sciences part 2
In our second of three reports on the 2026 Sunday Times Tech 100, we focus on the first nine of 18 life sciences companies in the hardware category.
NICE approves new COPD treatment that cuts flare-ups by 30%
NICE has recommended dupilumab, a first-of-its-kind targeted COPD treatment that reduces flare-ups and improves lung function, offering new hope to thousands of patients The National Institute for Health and Care Excellence (NICE) has recommended dupilumab, an innovative biologic therapy for adults with chronic obstructive pulmonary disease (COPD), marking a major advancement in treatment options. This […]